Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | PTGIR | P43119 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650590 | 0.90 | ALDH1A1 (0.57) | MEN1KMT2ARAB9AALDH1A1CYP2D6 | |
| SCHEMBL22488317 | 0.90 | ALDH1A1 (0.57) | MEN1KMT2ARAB9AALDH1A1CYP2D6 | |
| SCHEMBL22488321 | 0.90 | ALDH1A1 (0.57) | MEN1KMT2ARAB9AALDH1A1CYP2D6 | |
| SCHEMBL26100694 | 0.88 | MCHR1 (0.59) | MEN1KMT2ARAB9AALDH1A1CYP2D6 | |
| SCHEMBL8320248 | 0.85 | HRH3 (0.69) | MEN1KMT2ASIGMAR1SMN1; SMN2HRH3 | |
| SCHEMBL621695 | 0.84 | HRH3 (0.62) | MEN1KMT2ASIGMAR1SMN1; SMN2HRH3 | |
| SCHEMBL19285228 | 0.84 | SIGMAR1 (0.85) | ALDH1A1SIGMAR1SMN1; SMN2PTGIRCHKA | |
| SCHEMBL20804352 | 0.84 | SIGMAR1 (0.85) | ALDH1A1SIGMAR1SMN1; SMN2PTGIRCHKA | |
| SCHEMBL1043952 | 0.84 | SIGMAR1 (0.85) | ALDH1A1SIGMAR1SMN1; SMN2PTGIRCHKA | |
| SCHEMBL1586714 | 0.83 | SIGMAR1 (0.63) | MEN1KMT2ASIGMAR1SMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9181220-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140179738-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8697727-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110306767-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-8012955-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| CN-102153544-A | Preparation method and application of novel tyrosine kinase inhibitors | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | disclosed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| EP-2079694-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | Rigel Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008083124-A1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-0871613-A1 | BENZYL PIPERIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-21 | — | — | EP | disclosed |
| US-5753679-A | SCIZOPHRENIA | HOFFMANN-LA ROCHE INC. (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1996035666-A1 | BENZYL PIPERIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 1996-11-14 | — | — | WO | disclosed |
| US-4639522-A | HYPOTENSIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1987-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306767-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | MEN1 3006/4885KMT2A 740/4885RAB9A 2654/4885 |
| US-20140179738-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | MEN1 3006/4885KMT2A 740/4885RAB9A 2654/4885 |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | MEN1 3006/4885KMT2A 740/4885RAB9A 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.